54258-24-1

Basic information

• Product Name: 5-Isoxazolecarbonyl chloride, 3-methoxy- (9CI)
• Synonyms: 5-Isoxazolecarbonyl chloride, 3-methoxy- (9CI)
• CAS NO: 54258-24-1
• Molecular Formula: C₅H₄ClNO₃
• Molecular Weight: 161.54316
• Product Categories: OXAZOLE;ACIDHALIDE
• Mol File: 54258-24-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Isoxazolecarbonyl chloride, 3-methoxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Isoxazolecarbonyl chloride, 3-methoxy- (9CI)(54258-24-1)
• EPA Substance Registry System: 5-Isoxazolecarbonyl chloride, 3-methoxy- (9CI)(54258-24-1)

Safety Data

• Hazardous Substances Data: 54258-24-1(Hazardous Substances Data)

Upstream product

• 13626-59-0 3-methoxyisoxazole-5-carboxylic acid 

Downstream Products

• 54258-29-6 3-Methoxy-5-propionylisoxazol 
• 55704-94-4 N-Methyl-3-methoxyisoxazol-5-carboxamid 
• 124953-44-2 4-(3-Methoxy-isoxazole-5-carbonyl)-piperazine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 
• 2763-94-2 5-aminomethyl-3-methoxyisoxazole 
• 54258-27-4 3-Methoxy-5-(1-hydroxyiminoaethyl)isoxazol 
• 54258-31-0 3-Methoxy-5-(1-aminopropyl)isoxazol 
• 1218792-23-4 C₂₈H₂₀ClF₂N₇O₄ 

Relevant articles and documents

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles

Two series of oxazolidinone derivatives having substituted isoxazoles were synthesized and tested for antibacterial activities against several Gram-positive strains including the resistant strains of Staphylococcus and Enterococcus, such as MRSA, CRSA, MSSA and VRE. Some of them showed in vitro activities (MIC) comparable or superior to the reference compound vancomycin.